Australia's most trusted
source of pharma news
Monday, 22 June 2026
Monday, 22 June 2026
Subscribe
Login
Novo hit with $105M ransom demand
Some of Novo Nordisk's biggest secrets - including "confidential recipes" for its top drugs appear to be for sale on the Dark Web after the pharma refused to bow down to hackers.
Industry body unveils new name
Entering its second decade, this well-known industry body has announced new branding, including a 'bold' new name
TODAY
Another pharma cuts Aussie jobs
Yet another Big Pharma has downsized its Australian workforce as part of a global restructure designed to realign resources
TODAY
TGA flooded with new drug labels
Australia's regulator has accepted 18 new indication applications for evaluation, with new cancer labels making up more than half the list
19 June
PBAC agenda tops 60 submissions
Five submissions added and one moved to a future meeting in version 4 of the PBAC's July agenda
19 June
Ex-Novartis boss tells what's next
Former Novartis boss Ali Rossiter has made a brief statement and will take some time before her next career move
18 June
Aussie book tackles pharma burnout
A former Australian pharma executive has penned a field guide to help industry professionals perform under increasing pressure
18 June
Latest Jobs
HR ConsultantRegulatory Affairs ManagerHead of Access, Sustainability & External EngagementSenior Quality Assurance AssociateMedical ReceptionCustomer Service RepresentativeCustomer Service Representative - VictoriaCustomer Service Representative34 more...
Pharma in Focus Jobs
Marketing & Communications (2)
Sales & Customer Relations (20)
- Customer Service Representative - Sydney
- Customer Service Representative - Victoria - Mulgrave
- Customer Service Representative - Perth
- Territory Manager - Auckland
- Senior Sales Manager - Sydney
- Clinical Account Manager - Melbourne
- Account Manager - Sydney
- Territory Manager - Sydney
- Pharmaceutical Sales Representative - Brisbane
- Customer Service Representative - Macquarie Park
- Customer Service Representative - Macquarie Park
- Senior Director, Business Development - Clinical Research - Tokyo, Japan
- Senior Director, Business Development - Clinical Research (Tokyo Based) - Tokyo, Japan
- Equipment Sales Specialist - Dental - Sydney
- Territory Manager - Melbourne
- Key Account Manager - Melbourne
- Senior Group Financial Accountant - Victoria
- Strategic Sales Director ANZ, Digital Health - Sydney
- Strategic Sales Director ANZ, Digital Health - Melbourne
- Sales Manager / Territory Manager - Christchurch
Access & Reimbursement (2)
- Head of Access, Sustainability & External Engagement - Melbourne
- Associate Director / Senior Manager, Market Access (ANZ) - Melbourne
Clinical & Medical, R&D (8)
- Medical Reception - West Perth
- Clinical Account Manager - Melbourne
- Senior Medical Science Liaison - Sydney
- Associate Director, Clinical Operations (Japan) - Tokyo, Japan
- Senior Director, Business Development - Clinical Research - Tokyo, Japan
- Senior Director, Business Development - Clinical Research (Tokyo Based) - Tokyo, Japan
- Clinical Trial Investigator - Melbourne
- Senior Medical Manager - Melbourne
Regulatory, Pharmacovigilance & QA (6)
- Regulatory Affairs Manager - Belrose
- Senior Quality Assurance Associate - Randwick
- Country Head, Regulatory Affairs, ANZ - Melbourne
- Senior Quality Assurance Manager - Sydney
- Quality Control Systems Specialist - Tullamarine
- Director - Regulatory Affairs - Melbourne
Executive Roles (7)
- Associate Director / Senior Manager, Market Access (ANZ) - Melbourne
- Associate Director, Clinical Operations (Japan) - Tokyo, Japan
- Senior Director, Business Development - Clinical Research - Tokyo, Japan
- Senior Director, Business Development - Clinical Research (Tokyo Based) - Tokyo, Japan
- Director - Regulatory Affairs - Melbourne
- Strategic Sales Director ANZ, Digital Health - Sydney
- Strategic Sales Director ANZ, Digital Health - Melbourne
Other (8)
Price moves get mixed PBAC result
The PBAC agreed with two price adjustments and knocked back a third at its May Intracycle meeting. See who missed out
TODAY
Pfizer's $53M drug under threat
TGA approves first generic of this big earning drug as well as a medicine accepted for review more than two years ago
TODAY Approvals Action
Leaders 'sleep rough' for a cause
Pharma bosses have again braved the elements to raise awareness and funds to address homelessness in Australia
19 June
Will evolutionary drug be funded?
A new treatment described as "an evolution" has been approved by the TGA, but getting a PBS subsidy is expected to be challenging
19 June
Eyes on August PBS listing
A decision to pull a 35-year-old drug from the market could see an alternative product - and the most popular strength - listed on the PBS
19 June
World congress hits Australia
A world medical congress will be held in Oceania for the first time in its history, overlooking the Yarra River in Melbourne
18 June
Cheeky Novartis plan rebuffed
A spirited attempt to remove the trademark for a rival PBS-listed heart drug has been denied by IP Australia
18 June
Brand success decided pre-launch
How well a new drug does in real world prescribing is based on how well the launchpad is constructed, new research has found
18 June
New Aussie Country Leader named
This company has been shuffling its upper ranks and there's a new boss in town but he's not the only one who's been promoted
17 June
Locals nab half-a-billion-dollar deal
Up to $467M is in the works for a local biotech on top of $14M upfront in a licensing deal with one of the largest markets in the world
17 June
Aussie pharma class action boom
Australia is the second most active class action jurisdiction globally, and the health sciences industry expects it to get worse
17 June
161 adverse events sparks warning
The TGA has issued a warning to HCPs just days after the NSW Govt expanded funded access to this product
17 June
BioNTech's Aussie site nears finish
The manufacturing site has hit a major milestone with construction expected to be completed later this year
17 June
Novartis boss surprise resignation
After taking the top job just three months ago, Ali Rossiter has resigned for personal reasons with an interim leader stepping in
16 June